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Abstract
Following chemotherapy, secondary acute myeloid leukemia (sAML), occurring after antecedent hematologic diseases,
previous chemotherapy or radiation, has an inferior prognosis compared with de novo AML. To deﬁne the outcome of
sAML in the context of allogeneic stem cell transplantation (alloSCT), a retrospective, registry-based comparison was
performed, including 11,439 patients with de novo and 1325 with sAML. Among transplants in ﬁrst complete
remission (CR1) (n= 8,600), the 3-year cumulative incidence of relapse (RI) and non-relapse mortality (NRM) was 28.5%
and 16.4% for de novo, and 35% and 23.4% for sAML. Three-year overall survival (OS), leukemia-free survival (LFS) and
Graft-versus-Host Disease/relapse-free survival (GRFS) was 60.8%, 55.1%, and 38.6% for de novo, and 46.7%, 41.6%, and
28.4% for sAML, respectively. In multivariate analysis, sAML was associated with a lower OS (HR= 1.33 [95% CI=
1.21–1.48]; p < 10−5), LFS (HR= 1.32 [95% CI= 1.19–1.45]; p < 10−5) and GRFS (HR= 1.2 [95% CI= 1.1–1.31]; p < 10−4)
and higher NRM (HR= 1.37 [95% CI= 1.17–1.59]; p < 10−4) and RI (HR= 1.27 [95% CI= 1.12–1.44]; p < 10−3). Results of
the Cox model were conﬁrmed in a matched-pair analysis. In contrast, results did not differ between de novo and
sAML after alloSCT in induction failure or relapse. Hence, this analysis identiﬁed sAML as an independent risk factor for
outcome after alloSCT in CR1.
Introduction
Secondary acute myeloid leukemia (sAML) arises from
underlying hematological disorders such as myelodys-
plastic syndrome (MDS), myeloproliferative neoplasm
(MPN), MPN/MDS overlap or bone marrow failure syn-
dromes. Furthermore, therapy related AML (tAML),
which can develop after a prior treatment by che-
motherapy or radiation, can be assigned to the sAML
classiﬁcation1.
Treating sAML with conventional chemotherapy or
autologous stem cell transplantation is associated with a
poor prognosis2–4. Therefore, in comparison to de novo
AML, sAML is thought to have an inferior prognosis in
general5–7. Allogeneic stem cell transplantation (alloSCT)
is regarded as the treatment option for sAML with the
best chance of achieving a long-term remission. Con-
sidering the transplant setting8,9, patients with sAML tend
to have less available HLA identical siblings, and the
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majority receive reduced intensity conditioning (RIC)10,11.
However, it is not clear whether having sAML per se is a
risk factor for outcome after alloSCT, when all well-
known risk factors are controlled for8.
So far, only smaller studies have addressed this ques-
tion12. Therefore, the Acute Leukemia Working Party
(ALWP) of the European Society of Blood and Marrow
Transplantation (EBMT) performed a retrospective
registry-based analysis, comparing the outcome of adult
patients diagnosed with sAML and de novo AML, who
had received alloSCT.
Methods
Study design
Data were provided by the EBMT registry, which
comprises more than 600 transplant centers providing
reports and annual follow-up on all consecutive stem cell
transplantations. Audits are routinely performed to
determine the accuracy of the data. Since 1990, patients
have provided informed consent, authorizing the use of
their personal information for research purposes. The
study was approved by the general assembly and review
board of the ALWP.
Inclusion criteria were age ≥ 18 years, alloSCT between
January 2000 and December 2016 from a matched related,
9/10 or 10/10 antigen matched unrelated, or a T-cell
replete haploidentical donor for either de novo or sAML,
and available information on cytogenetics. The number of
patients ﬁtting inclusion criteria was 11,439 patients with
de novo AML and 1325 with sAML.
Variables of interest were patient and donor char-
acteristics (age, gender, Karnofsky performance score
[KPS], cytomegalovirus [CMV] serostatus), disease-
related (favorable/intermediate/adverse cytogenetics
according to the British Medical Research Council clas-
siﬁcation13, remission status at alloSCT) and transplant-
related factors (graft source, donor type, conditioning, T-
cell depletion [TCD] and graft-versus-host disease
[GVHD] prophylaxis). Outcomes comprised overall sur-
vival (OS), leukemia free survival (LFS), GVHD/relapse-
free survival (GRFS), cumulative incidence of relapse (RI),
non-relapse mortality (NRM), acute and chronic GVHD,
and cause of death.
Deﬁnitions
Secondary AML was deﬁned as AML with an ante-
cedent MDS, MPN or other malignant hematologic dis-
order, bone marrow failure syndrome, or solid tumor with
prior chemotherapy or radiation8. For a subgroup analy-
sis, tAML was deﬁned by previous treatment of solid
tumors, Hodgkin or non-Hodgkin Lymphoma (NHL),
acute lymphoblastic leukemia (ALL) or chronic lympho-
cytic leukemia (CLL) using chemotherapy or radiation14.
As recommended complete remission (CR) was deﬁned
by <5% bone marrow (BM) blasts, absence of circulating
blasts and extramedullary disease. Failure to achieve CR
after two courses of standard induction chemotherapy
was deﬁned as primary induction failure (PIF). Relapse
was deﬁned by more than 5% BM blasts or reappearance
of circulating blasts after a documented CR15. OS was
deﬁned as the interval between day of alloSCT and day of
death or last follow-up, LFS as interval between alloSCT
and date of leukemia persistence, relapse or progression.
NRM was deﬁned as death from any cause without relapse
or progression. GRFS was deﬁned as absence of acute
GVHD III-IV, chronic GVHD requiring systemic treat-
ment, relapse, or death16,17. Reduced intensity con-
ditioning (RIC) was deﬁned using EBMT criteria18.
Cytogenetic subgroups were deﬁned according to SWOG
criteria19.
Statistical analysis
Descriptive statistics used median, inter-quartile range
(IQR), minimum (min) and maximum (max) for con-
tinuous data, counts and percentages for categorical
variables. Patient, disease, and transplant-related char-
acteristics for the two cohorts (de novo or secondary
AML) were compared by using χ2 statistics for categorical
variables and the Mann-Whitney test for continuous
variables. The date of transplantation was the starting
point for time-to-event analysis. Survivors were censored
at last contact. Cumulative incidence was used to estimate
the endpoints of NRM, RI, acute and chronic GVHD to
accommodate for competing risks. Relapse and death
were considered competing events for acute and chronic
GVHD. Probabilities of OS, LFS, and GRFS were calcu-
lated using the Kaplan–Meier method. Univariate ana-
lyses were done using the Gray’s test for cumulative
incidence functions and the log rank test for OS, GRFS,
and LFS.
A multivariate Cox proportional-hazards model was
performed to account for imbalances of risk factors
between the two cohorts. Due to a signiﬁcant interaction
between disease stage at transplant and diagnosis (de
novo or sAML), the analysis was stratiﬁed by stage at
alloSCT. All variables associated with a signiﬁcant out-
come in univariate analysis (p < 0.05), factors known from
the literature to have a potential inﬂuence on outcome,
and variables not equally balanced between cohorts were
included in the Cox model.
To conﬁrm the results from the Cox model, a matched-
pair analysis of secondary versus de novo AML was per-
formed, using the following criteria for matching: Age (±3
years), cytogenetics, stage at alloSCT, KPS, conditioning,
in and ex vivo TCD, donor type, donor/recipient gender
and CMV serostatus combinations, and graft source.
Schmaelter et al. Blood Cancer Journal           (2020) 10:26 Page 2 of 9
Blood Cancer Journal
Results were expressed as hazard ratio (HR) and 95%
conﬁdence intervals (CI). Proportional hazards assump-
tions were checked for all models using the Grambsch-
Therneau residual-based test. All tests were 2-sided. The
Type I error rate was ﬁxed at 0.05 for the determination of
factors associated with time-to-event outcomes. Statistical
analyses were performed with SPSS 24.0 (SPSS Inc,
Chicago, IL) and R 3.4.1 (https://www.R-project.org/).
Results
Patients’ disease and transplant characteristics
Using the criteria deﬁned above, 11,439 patients with de
novo AML and 1325 with sAML were included. Median
follow-up after alloSCT was 36.1 and 33.1 months for de
novo and sAML, respectively. Patients’ disease- and
transplant-related characteristics are outlined in Table 1.
Among patients with sAML, 825 (62.5%) had evolved
from previous myeloid malignancy (most frequently MDS
[68.5%], MPN [11.0%], and MDS/MPN overlap [13.3%])
or bone marrow failure syndrome. In 500 (37.7%) patients
sAML was treatment related, following chemotherapy or
radiation for other types of cancer, with breast cancer
(38.2%) being the most frequent malignancy, followed by
lymphoma (33.2%), other solid tumors (26.2%), ALL
(2.4%), and CLL and myeloma (<1% each). In the de novo
AML and sAML cohorts 6306 (55.1%) and 574 (43.3%),
respectively, received a myeloablative conditioning regi-
men (MAC), whereas 5,133 (44.9%) of de novo AML
patients and 751 (56.7%) of sAML patients were treated
with a RIC regimen (cf. supplemental Tables 1–2 for
details on conditioning and immunosuppression).
Outcomes
Engraftment was achieved in 11,133 (98.2%) and 1264
(96.6%) patients with de novo AML and sAML, respec-
tively. Three-year OS and LFS rates for the entire cohort
were 54.6% [53.6–55.6] and 48.9% [47.9–49.9] for de novo
AML and 43.1% [40.1–46] and 37.9% [35.1–40.8] for
sAML. Three-year NRM, RI, and GRFS were 18%
[17.3–18.8], 33% [32.1–34], and 34.3% [33.3–35.3]
respectively, for de novo and 24.8% [22.4–27.3], 37.3%
[34.5–40.1], and 25.8% [23.1–28.4], respectively, for
sAML. Overall incidence of acute GvHD grades II–IV and
chronic GvHD were 23.5% [22.7–24.3]/40.6% [39.6–41.6]
for de novo AML and 24.4% [22–26.8]/35.4% [32.6–38.1]
for sAML. The most frequent cause of death was the
reoccurrence of the original disease, other causes of death
are shown in supplemental Table S3.
Comparison between de novo and secondary AML
As mentioned above, a signiﬁcant interaction between
disease status at transplant and diagnosis (de novo or
sAML) was observed. Therefore, the analysis of the role of
sAML had to be stratiﬁed according to disease status at
Table 1 Patient, disease and transplant characteristics in
entire population.
Characteristic de novo AML sAML p
N 11439 (89.62%) 1325 (10.38%)
Age at SCT (year),
median, (range) (IQR)
49.3 (18–76.8)
(37.8–58.2)
57.7 (18.3–76)
(49.3–63.5)
<10−3
Year of SCT, median
(range) (IQR)
2011
(2000–2016)
(2007–2014)
2012
(2000–2016)
(2009–2014)
<10−3
Months diagnosis to
SCT, median (IQR)
5.6 (4.1–9.7) 4.7 (3.5–6.3) <10−3
Status at SCT
CR1 7691 (67.23%) 909 (68.6%) <10−3
CR2 2132 (18.64%) 93 (7.02%)
PIF 607 (5.31%) 199 (15.02%)
Relapse 1009 (8.82%) 124 (9.36%)
Donor to patient sex
No female to male 9188 (80.32%) 1096 (82.72%) 0.037
Female to male 2251 (19.68%) 229 (17.28%)
KPS at SCT
KPS < 80 553 (4.83%) 94 (7.09%) <10−3
KPS ≥ 80 10,886 (95.17%) 1231 (92.91%)
Donor
MSD 6405 (55.99%) 578 (43.62%) <10−3
UD 10/10 3281 (28.68%) 518 (39.09%)
UD 9/10 1035 (9.05%) 139 (10.49%)
Haploidentical donor 718 (6.28%) 90 (6.79%)
CMV status donor (D) and recipient (R)
D−/R− 2725 (23.82%) 300 (22.64%) 0.005
D+/R− 1060 (9.27%) 112 (8.45%)
D−/R+ 2524 (22.06%) 350 (26.42%)
D+/R+ 5130 (44.85%) 563 (42.49%)
Cytogenetics
Favorable 1492 (13.04%) 58 (4.38%) <10−3
Intermediate 7809 (68.27%) 836 (63.09%)
Adverse 2138 (18.69%) 431 (32.53%)
Graft source
Bone marrow 2005 (17.53%) 162 (12.23%) <10−3
Peripheral blood 9431 (82.47%) 1163 (87.77%)
Conditioning regimen
MAC 6306 (55.13%) 574 (43.32%) <10−3
RIC 5133 (44.87%) 751 (56.68%)
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time of alloSCT. We focused on the comparison of
patients transplanted in CR1, primary refractory phase
and relapse, as only 93 patients with sAML were reported
to have been transplanted in CR2, precluding relevant
adjustment in that subgroup.
Transplantation in ﬁrst complete remission
Transplantation in CR1 had been performed in 7691
(67.2%) patients with de novo and 909 (68.6%) with
sAML. Three-year cumulative RI and NRM after alloSCT
was 28.5% and 16.4% for de novo AML and 35% and
23.4% for sAML, respectively. Three-year OS, LFS and
GRFS were 60.8%, 55.1%, and 38.6%, respectively, for de
novo and 46.7%, 41.6%, and 28.4%, respectively, for sAML
(all p-values < 10–5) (Fig. 1, Table 2).
In a multivariate Cox model, sAML was associated with
a lower OS (HR= 1.33 [1.21–1.48]; p < 10–5). Other
prognostic factors for OS after alloSCT in CR1 were age
(HR= 1.19 [1.15–1.23]; p= < 10−5), cytogenetics (inter-
mediate, HR= 1.27 [1.09–1.48]; p= 0.002, adverse, HR=
2 [1.7–2.35]; p= <10−5), patient/donor sex combination
(female in male, HR= 1.12 [1.03–1.22]; p= 0.007), KPS >
80% (HR= 0.66 [0.56–0.79]; p < 10−5) and donor type
(10/10 matched unrelated donor [UD], HR= 1.14
[1.04–1.24]; p= 0.007; 9/10 matched UD, HR= 1.36
[1.19–1.56]; p < 10−5; haploidentical donor, HR= 1.33
[1.11–1.6]; p= 0.002) (Table 3).
Regarding other outcome parameters, multivariate
analysis showed that sAML was associated with a lower
LFS (HR= 1.32 [1.19–1.45]; p < 10−5) and GRFS (HR=
1.2 [1.1–1.31]; p < 10−4), a higher NRM (HR= 1.37
[1.17–1.59]; p < 10−3) and RI (HR= 1.27 [1.12–1.44]; p <
10−4). Detailed results of a Cox model of risk factors for
RI, NRM, LFS, and GRFS are shown in supplemental
Tables 4–7. The inferior outcome of patients with sAML
was also observed in an exploratory subgroup analysis of
patients below and above the age of 60 years (data not
shown).
Separate comparison for AML evolving from myeloid
malignancies/bone marrow failure syndromes and
treatment-related AML
To evaluate a potential difference among patients with
sAML evolving from myeloid malignancies or bone
marrow failure syndromes versus treatment-related AML,
a second Cox model was ﬁtted, including the two subtypes
of sAML as covariates. Both sAML after myeloid malig-
nancies/BM failure and tAML were associated with
increased OS, LFS, and GRFS following alloSCT in CR1
when compared to de novo AML (supplemental Table S8).
Transplantation in primary induction failure or active
relapse
Among patients with sAML, 199 (15.02%) and 124
(9.36%) had been transplanted in PIF and relapsed disease,
respectively; in de novo AML, 607 (5.3%) had PIF, and
1009 (8.82%) had relapsed disease at time of alloSCT. In
contrast to the cohort transplanted in CR1, sAML was not
identiﬁed as a relevant factor for OS (PIF: HR= 0.92; p=
0.465; relapse: HR= 0.95; p= 0.64; cf. Tables 2 and 3),
nor for RI, NRM, LFS, and GRFS. Risk factors that
affected OS, RI, LFS, and GRFS in the cohort transplanted
for active disease included cytogenetics and KPS > 80% (cf.
Table 3 and supplemental Tables 4–7 for details).
Role of sAML for GVHD
Independently of disease status before transplantation,
sAML was not a risk factor for the occurrence of acute or
chronic GVHD. Risk factors for acute GVHD grade II–IV
across all subgroups were donor type, female donor for
male patient and in vivo TCD. In the CR1 cohort, among
others, age, cytogenetics, KPS, and conditioning regime
were additional factors. Risk of chronic GVHD was
mainly determined by graft source and in vivo TCD. In
CR1, age, female donor to male recipient and donor type
were additional factors (supplemental Tables 9–10 or
details).
Matched-pair analysis
To conﬁrm the results from the Cox model, a matched-
pair comparison was performed between de novo and
sAML. Using the criteria mentioned above, 877 well-
matched pairs were identiﬁed (cf. supplemental Table
S11). The matched-pair analysis conﬁrmed the ﬁndings of
the Cox model: Overall, sAML was associated with a
lower 3-year cumulative incidence of OS of 46.9% (95%
CI, 43.3–50.5) compared to 53.9% (95% CI, 50.1–57.7) in
de novo AML (p= 0.01). Furthermore, patients with
sAML had a lower LFS (p= 0.03), GRFS (p= 0.04), and a
higher NRM (p= 0.01). However, when the analysis was
stratiﬁed by disease status at alloSCT, again differences
were only seen among patients transplanted in CR1 (719
pairs, 82%). The 3-year OS in the CR1 sAML and in the de
Table 1 continued
Characteristic de novo AML sAML p
T-cell depletion (TCD)
No in vivo TCD 5951 (52.02%) 502 (37.89%) <10−3
In vivo TCD 5488 (47.98%) 823 (62.11%)
No ex vivo TCD 10964 (95.85%) 1305 (98.49%) <10−3
Ex vivo TCD 475 (4.15%) 20 (1.51%)
Graft source: 3 missing in de novo AML group.
Details on conditioning regimes are presented in supplemental Table S1.
Details on immunosuppression are presented in supplemental Table S2.
SCT stem cell transplantation, IQR interquartile range, CR complete remission, PIF
primary induction failure, KPS Karnofsky performance status, MSD matched
sibling donor, UD unrelated donor, CMV cytomegalovirus, MAC myeloablative
conditioning, RIC reduced-intensity conditioning, TCD T-cell depletion.
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novo AML cohort was 48.1% (95% CI, 44–52.1) and 57.4%
(95% CI, 53.2–61.6) (p= 0.0004), respectively. In contrast,
no signiﬁcant difference in OS was observed between
secondary and de novo AML after alloSCT in PIF (67
pairs, 7.6%, p= 0.58) and relapse (44 pairs, 5%, p= 0.20).
Results of the matched pair analysis are shown in Table 4.
Discussion
In this large-scale, registry-based analysis, a multivariate
model identiﬁed sAML as an independent risk factor for
OS, LFS, GRFS, RI, and NRM after alloSCT in CR1, as
compared to de novo disease. A matched-pair analysis
conﬁrmed these ﬁndings, which were observed both in
treatment-related AML and AML evolving from other
myeloid disorders or BM failure syndromes. In contrast,
in patients with active disease at alloSCT, with relapse
being by far the most frequent cause of treatment failure,
the classical risk factors such as cytogenetics, age and KPS
determined outcome. Secondary AML had no inﬂuence
on outcome in the context of the aggressive nature of
advanced disease.
Patients diagnosed with sAML tend to be of older age,
carry more unfavourable cytogenetics and show poor
response to chemotherapy20,21. Regardless of cytogenetics
and preceding therapy of antecedent haematological dis-
eases, sAML is known to have a poor long-term remission
even when using aggressive induction therapy22,23. Sepa-
rate studies on patients with treatment-related AML fol-
lowing intensive chemotherapy, identiﬁed tAML as an
independent adverse prognostic factor2,7,14,24. However,
Fig. 1 Outcome of patients with either de novo or secondary AML after alloSCT in CR1. RI Incidence of relapse, OS Overall survival, NRM Non-
relapse mortality, LFS Leukemia-free survival (p= 8.6 × 10−5, NRM: p < 10−5, LFS: p < 10−5, OS: p < 10−5).
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data on the role of sAML as a risk factor for outcome after
alloSCT are scarce. Michelis et al. reported on a total of
264 patients with sAML and de novo AML, transplanted
in CR112. Age, hematopoietic cell transplant comorbidity
index, and karyotype were considered for matching. In
contrast to our results, no clear inﬂuence of having sAML
could be demonstrated regarding OS, NRM, LFS, and RI
after alloSCT, using multivariate analysis and a propensity
score model. It can be speculated, that the lower patient
numbers precluded Michelis at al. from detecting a sta-
tistically signiﬁcant difference (p= 0.18), given that the
3-year OS in their cohort was 55% for de novo and 46%
for sAML.
Besides the classical risk factors, i.e., cytogenetics and
age, as well as donor type, our data identify sAML as an
independent intrinsic factor for inferior outcome after
alloSCT in CR1. Both patient and disease speciﬁc factors
might contribute to this ﬁnding. First, characteristics
associated with NRM (i.e., age, HLA mismatch, female
donor to male patient, CMV seropositivity) had a high
impact on OS in patients with sAML. This observation
could suggest a lower ability to generally tolerate side
effects and complications in the context of alloSCT, such
as toxicity of the conditioning and immunosuppression,
infections and GVHD. It might be a consequence of prior
chemotherapy given for the antecedent hematologic or
solid organ tumors, and might not be reﬂected by the
performance score at time of alloSCT among patients
with sAML21,25. Second, given the higher number of
patients with sAML who have adverse cytogenetics,
indicating lower sensitivity to standard chemotherapy and
hypomethylating agents, the quality of CR might generally
be inferior in sAML as compared to de novo disease. A
better remission quality, however, is decisive for the
outcome after alloSCT in sAML26, as well as de novo
AML27,28. Third, the more aggressive nature of a sec-
ondary malignancy as such might play a role in the
inferior outcome of patients with sAML, when trans-
planted in CR1.
Previous reports have suggested, that AML following
antineoplastic radiation or chemotherapy (tAML) be
considered an independent entity25. Although there are
no pathognomonic genetic aberrations known for tAML,
this subgroup had a worse outcome than MDS-related
AML in several studies2,7,14,24. In a previous study from
our group, slight differences in NRM and survival had
been observed between patients with AML evolving from
MDS/MPN and other hematologic malignancies, but not
solid tumors8. In the present analysis, we therefore repe-
ated the Cox model including tAML and AML evolving
from another hematologic disease, as covariates. Both
subgroups achieved comparable outcomes and were
associated with increased OS, LFS and GRFS following
alloSCT in CR1. Hence, as suggested earlier, the described
two subtypes might be grouped as sAML in the setting of
alloSCT12, although our numbers were to small to com-
pare outcome of sAML following MDS versus sAML
versus MPN.
Table 2 OS, Relapse, NRM, LFS, and GRFS at 3 years (univariate analysis).
CR1 PIF Rel
OS de novo AML 60.8% [59.6–62] 29.8% [25.6–34] 23.6% [20.7–26.4]
sAML 46.7% [43.1–50.3] 35.7% [28.5–42.9] 24.8% [16.7–33]
p (log rank) <10−5 0.541 0.721
Relapse de novo AML 28.5% [27.4–29.6] 53% [48.6–57.3] 58.4% [55.1–61.5]
sAML 35% [31.7–38.4] 43% [35.6–50.1] 49.5% [40–58.2]
p (log rank) 8.6 x 10−5 0.05 0.089
NRM de novo AML 16.4% [15.5–17.3] 21.2% [17.9–24.7] 23% [20.3–25.7]
sAML 23.4% [20.5–26.4] 27.9% [21.5–34.6] 30.3% [22.2–38.7]
p (log rank) <10−5 0.027 0.115
LFS de novo AML 55.1% [53.8–56.3] 25.8% [21.9–29.7] 18.7% [16.1–21.3]
sAML 41.6% [38–45.1] 29.1% [22.3–36] 20.3% [12.8–27.8]
p (log rank) <10−5 0.753 0.674
GRFS de novo AML 38.6% [37.4–39.9] 16.8% [13.5–20.2] 13.8% [11.6–16.1]
sAML 28.4% [25.1–31.6] 16.2% [10.5–21.9] 16.3% [9.5–23.2]
p (log rank) <10−5 0.981 0.448
OS overall survival, NRM non-relapse mortality, LFS leukemia-free survival, GRFS Graft-versus-Host Disease/relapse-free survival, CR complete remission, PIF primary
induction failure, Rel relapse.
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Due to the retrospective nature of our study, some
limitations, including missing information on MRD status
and pre- and post-transplant therapies in most patients,
must be acknowledged. In addition, there is a risk of
selection bias, as patients without information on cyto-
genetics were deliberately excluded from this analysis,
considering the high relevance of cytogenetic subgroups
for outcome. Nevertheless, overall outcome data in our
cohort are comparable to data from other studies8, sug-
gesting that the cohort was representative. It must also be
acknowledged that information on molecular aberrations
was available only in a minority of patients from both
cohorts and could therefore not be considered. However,
in contrast to cytogenetic aberrations, which without
doubt have similarly strong prognostic value in both de
novo and sAML, less is known on the comparable value of
molecular markers in both subgroups, which is why
inclusion of these markers in this comparison would be
difﬁcult. Further, in the matched-pair analysis, patients
with sAML and especially those in CR2 are most probably
underrepresented, and fewer patients than expected could
ﬁnally be included in the model. Therefore, the matched-
pair analysis can only be regarded as conﬁrmatory for the
overall results obtained from the Cox model, which
included all patients, and failed to reproduce the increased
risk of relapse in sAML, most likely due to limited
numbers.
This large-scale retrospective study identiﬁed sAML as
an independent risk factor for alloSCT in CR1. Both the
inferior quality of CR and higher sensitivity to toxicity
might have contributed to the inferior outcome of sAML.
These data help to improve risk stratiﬁcation and prog-
nostic estimates after alloSCT for sAML. Furthermore,
the results may contribute to the design of optimized
transplant protocols. Previous studies have suggested
comparable outcomes after RIC and MAC in sAML,
however, with a trend for better outcome after MAC11,29.
Hence, a myeloablative, but reduced toxicity conditioning
regimen such as the combination of Fludarabine and
Treosulfan30 might be of particular value in patients with
Table 3 Multivariate analysis of risk factors for overall survival, stratiﬁed by stage at transplantation.
SCT in CR1 SCT in PIF SCT in relapse
HR CI p HR CI p HR CI p
sAML 1.33 1.21–1.48 <10−5 0.917 0.726–1.157 0.46499 0.946 0.752–1.192 0.640
Age (per 10 years) 1.18 1.15–1.225 <10−5 1.103 1.025–1.188 0.009 1.051 0.994–1.112 0.081
Year of SCT 0.996 0.987–1.006 0.441 0.971 0.949–0.994 0.015 0.999 0.981–1.018 0.919
Relapse 2 vs relapse 1 n.a. n.a. 1.232 1.029–1.475 0.023
Favorable cytogenetics (ref) 1 1 1
Intermediate 1.27 1.088–1.482 0.002 n.a. n.a. n.a.
Adverse 1.996 1.696–2.349 <10−5 1.653 1.374–1.988 <10−5 1.368 1.163–1.609 <10−4
Female donor to male recipient 1.124 1.033–1.224 0.007 1.255 1.013–1.555 0.037 1.155 0.972–1.373 0.102
Previous autograft 1.371 1.012–1.857 0.041 n.a. n.a.
KPS > 80% 0.662 0.555–0.789 <10−5 0.517 0.405–0.66 <10−5 0.56 0.464–0.676 <10−5
MSD (ref) 1 1 1
UD 10/10 1.135 1.036–1.243 0.007 1.043 0.809–1.345 0.746 0.806 0.668–0.973 0.025
UD 9/10 1.361 1.189–1.558 10−5 0.98 0.7–1.371 0.904 1.17 0.933–1.468 0.174
Haploidentical donor 1.333 1.11–1.602 0.002 1.304 0.905–1.88 0.154 0.912 0.705–1.179 0.482
PB vs BM 1.002 0.907–1.106 0.976 0.93 0.672–1.286 0.660 0.804 0.648–0.998 0.048
Patient CMV-positive 1.094 1.011–1.183 0.025 1.24 1.006–1.53 0.044 1.028 0.874–1.209 0.738
Donor CMV-positive 0.968 0.899–1.042 0.386 1.048 0.861–1.275 0.643 1.101 0.947–1.28 0.209
MAC vs RIC 1.026 0.94–1.12 0.570 1.01 0.823–1.24 0.923 1.062 0.91–1.239 0.448
In vivo T-cell depletion 0.935 0.859–1.018 0.122 0.887 0.703–1.119 0.311 1.108 0.939–1.308 0.223
SCT stem cell transplantation, CR complete remission, PIF primary induction failure, HR hazard ratio, CI conﬁdence interval, ref reference, KPS Karnofsky performance
status, MSD matched sibling donor, UD unrelated donor, PB peripheral blood, BM bone marrow, CMV cytomegalovirus, MAC myeloablative conditioning, RIC reduced-
intensity conditioning.
Statistically signiﬁcant values are marked in bold.
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sAML. In addition, strategies to improve the quality of
remission prior to alloSCT in those patients with fre-
quently low sensitivity to chemotherapy might be of
particular importance31.
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